1-20 of 100
Authors: D T Rubin
Journal Article
P0801 Real-world Effectiveness and Tolerability of Etrasimod in Active Ulcerative Colitis: A 26-week Observational Study Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i1537, https://doi.org/10.1093/ecco-jcc/jjae190.0975
Published: 22 January 2025
Journal Article
P1001 Efficacy and safety of an oral tyrosine kinase 2 inhibitor VTX958 in moderately to severely active Crohn’s disease: a randomised, double-blind, placebo-controlled, phase 2 trial Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i1853–i1854, https://doi.org/10.1093/ecco-jcc/jjae190.1175
Published: 22 January 2025
Journal Article
DOP018 Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programme Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i119–i121, https://doi.org/10.1093/ecco-jcc/jjae190.0057
Published: 22 January 2025
Journal Article
DOP060 Early disease efficacy of guselkumab therapy in biologic-naïve patients with moderately to severely active Crohn’s disease: Post-hoc analysis from the phase 3 GALAXI 2 & 3 studies Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i202–i203, https://doi.org/10.1093/ecco-jcc/jjae190.0099
Published: 22 January 2025
Journal Article
P0705 Features of optimal disease control in Crohn’s disease and Ulcerative Colitis: Views on IBD Expectations and Well-being by Patients and Treatment providers Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i1376–i1377, https://doi.org/10.1093/ecco-jcc/jjae190.0879
Published: 22 January 2025
Journal Article
P0669 Safety of intravenous and subcutaneous guselkumab induction administration: Results from the GALAXI and GRAVITI studies in participants with Crohn’s Disease Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i1308–i1309, https://doi.org/10.1093/ecco-jcc/jjae190.0843
Published: 22 January 2025
Journal Article
P0390 Development, internal, and external validation of a novel endoscopic activity score for evaluation of Crohn’s disease (EASE-CD) Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i881–i882, https://doi.org/10.1093/ecco-jcc/jjae190.0564
Published: 22 January 2025
Journal Article
P0734 Real-World Experience of Curcumin+Qing Dai Reduces Biochemical and Intestinal Ultrasound Disease Markers in Patients with Inflammatory Bowel Disease Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i1424–i1426, https://doi.org/10.1093/ecco-jcc/jjae190.0908
Published: 22 January 2025
Journal Article
P0061 Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction study Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i421–i422, https://doi.org/10.1093/ecco-jcc/jjae190.0235
Published: 22 January 2025
Journal Article
OP10 Efficacy and safety of subcutaneous guselkumab induction therapy in patients with Ulcerative Colitis: Results through week 12 from the phase 3 ASTRO study Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i19–i20, https://doi.org/10.1093/ecco-jcc/jjae190.0010
Published: 22 January 2025
Journal Article
P0279 Assessing patient-reported health status in moderate-to-severe Crohn’s Disease and Ulcerative Colitis: Results from the communicating needs and features of IBD experiences (CONFIDE) survey Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i719–i720, https://doi.org/10.1093/ecco-jcc/jjae190.0453
Published: 22 January 2025
Journal Article
P0264 Using a machine learning model to grade clip-level endoscopic inflammation reveals the heterogeneity of mucosal inflammation in ulcerative colitis Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i697–i698, https://doi.org/10.1093/ecco-jcc/jjae190.0438
Published: 22 January 2025
Journal Article
P0638 Impact of immunogenicity on 2-year clinical outcomes in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab: A post hoc analysis of the Phase 3 LIBERTY-CD study Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i1254–i1255, https://doi.org/10.1093/ecco-jcc/jjae190.0812
Published: 22 January 2025
Journal Article
P0701 Trans-continental analysis of determinants of response to COVID-19 vaccination in 2268 patients with Inflammatory Bowel Disease Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i1369–i1371, https://doi.org/10.1093/ecco-jcc/jjae190.0875
Published: 22 January 2025
Journal Article
P0810 Anti TNF Treatment is Associated with Reduced Risk of Diabetes in Patients With Inflammatory Bowel Disease Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i1550, https://doi.org/10.1093/ecco-jcc/jjae190.0984
Published: 22 January 2025
Journal Article
DOP014 Efficacy and safety up to 3 years of risankizumab maintenance treatment in patients with moderately to severely active ulcerative colitis: interim results from phase 3 COMMAND open-label extension study Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i108–i110, https://doi.org/10.1093/ecco-jcc/jjae190.0053
Published: 22 January 2025
Journal Article
DOP099 Prolonged Pharmacodynamic Effects of Risankizumab Following Withdrawal in Patients with Moderately to Severely Active Ulcerative Colitis Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i264–i265, https://doi.org/10.1093/ecco-jcc/jjae190.0138
Published: 22 January 2025
Journal Article
DOP069 Guselkumab maintenance therapy mediates further improvements in intestinal immune homeostasis and mucosal healing in patients with ulcerative colitis Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i214–i215, https://doi.org/10.1093/ecco-jcc/jjae190.0108
Published: 22 January 2025
Journal Article
DOP105 Patient-reported quality of life in moderate-to-severe Crohn’s Disease and Ulcerative Colitis: Insights from the communicating needs and features of IBD experiences (CONFIDE) survey Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i275–i276, https://doi.org/10.1093/ecco-jcc/jjae190.0144
Published: 22 January 2025
Journal Article
P0608 Safety of guselkumab in Inflammatory Bowel Disease up to 1 year: Integrated safety analysis of phase 2 and 3 studies in Crohn’s Disease and Ulcerative Colitis Free
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i1205–i1207, https://doi.org/10.1093/ecco-jcc/jjae190.0782
Published: 22 January 2025
